Latest Laboratory Corporation of America Holdings (LH) Headlines
Myriad Genetics Down on Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:30PM CDT
Shares of Myriad Genetics slashed 8.34% at yesterday's close, soon after an unfavorable court bid.
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
Business Wire - Tue Mar 11, 4:05PM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that for the period of March 12, 2014 to September 11, 2014, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2014, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.56 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 27, 2014. The payment of contingent cash interest is expected to be made on September 11, 2014.
Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ
ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ
XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
LabCorp is Scheduled to Present at the Barclays Capital 2014 Global Healthcare Conference
Business Wire - Tue Mar 04, 4:05PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2014 Global Healthcare Conference in Miami Beach, FL. LabCorp's presentation is planned for Tuesday, March 11, 2014 at 10:45 AM (Eastern Time).
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Must-See Charts: 5 Big Charts to Trade for Gains
at The Street - Thu Feb 27, 10:44AM CST
Here's a look at how to trade some of the biggest names on Wall Street.
Global Endocrine Testing Market to 2019: E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests
M2 - Wed Feb 26, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bk2st3/endocrine_testing) has announced the addition of the "Global Endocrine Testing Market to 2019: E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests" report to their offering. Endocrinology, a branch of medicine deals with the study of structural and functional elements of the endocrine system. This system comprises endocrine glands (thyroid, adrenal, pituitary and others) and secretory organs (pancreas, hypothalamus) that release hormones directly into the blood stream and regulate the body functioning. Endocrine testing market is studied by three major segments namely, by test, by diagnostic technologies and by end users. The test segment is further classified into 11 major hormone tests that includes estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The market accounts for a wide range of conventional as well as rapid diagnostic kits used for detecting deficiency (hyposecretion) or excess (hypersecretion) secretions of these hormones. The diagnostic technologies segment further describes the technological platforms used in the analysis of the specimen test sample (blood, urine, etc) and is further categorized into five major technologies, tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody, sensor and clinical chemistry technologies. The end user segment elucidates the endocrine testing market by various end users that includes hospitals, commercial laboratories, ambulatory health care centers, home based tests and physician's offices. The global endocrine testing market is segmented into the following categories: Tests - Estradiol (E2) Test - Follicle Stimulating Hormone (FSH) Test - Human Chorionic Gonadotropin (hCG) Test - Luteinizing Hormone (LH) Test - Dehydroepiandrosterone sulfate (DHEAS) Test - Progesterone Test - Testosterone Test - Thyroid Stimulating Hormone (TSH) Test - Prolactin Test - Cortisol Test - Insulin Test - Others (Gastrin, Thymosin, Secretin, etc.) Diagnostic Technologies - Tandem Mass spectrometry - Immunoassay (Enzyme immunoassays, Radioimmunoassays (RIA)) Technologies - Monoclonal and Polyclonal Antibody Technologies - Sensor (Electrochemical, Biosensors, etc.) Technologies - Clinical Chemistry Technologies - Others (Liquid Chromatography Mass Spectrometry (LC-MS), High performance Liquid Chromatography (HPLC), etc.) Location - Hospitals - Commercial Laboratories - Ambulatory Care Centers - Home Based Tests - Physician Offices Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Endocrine Testing Market, by Test Chapter 5 Endocrine Testing Market, by Diagnostic Technologies Chapter 6 Endocrine Testing Market, by End Users Chapter 7 Endocrine Testing Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned - Abbott Laboratories - AB SCIEX LLC - Agilent Technologies - Biomedical Diagnostics - bioMerieux - Bio-Rad Laboratories, Inc. - DiaSorin S.p.A - F. Hoffmann-La Roche Ltd. - Laboratory Corporation of America Holdings (LabCorp) - Ortho Clinical Diagnostics - Quest Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/bk...ne_testing
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
LabCorp Announces the Availability of Thermo Scientific ImmunoCAP(TM) Allergy Testing Products
Business Wire - Mon Feb 24, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the availability of Thermo Scientific ImmunoCAP(TM) allergy testing products from Thermo Fisher Scientific, Inc. (NYSE: TMO).
Illumina Expands in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:20PM CST
Recently, a HiSeq X Ten sequencing system of Illumina was acquired by a Chinese genomics service provider, Novogene.
Laboratory Corp of America Holdings Has Returned 10.5% Since SmarTrend Recommendation (LH)
Comtex SmarTrend(R) - Wed Feb 12, 11:22AM CST
SmarTrend identified a Downtrend for Laboratory Corp of America Holdings (NYSE:LH) on November 29th, 2013 at $102.32. In approximately 3 months, Laboratory Corp of America Holdings has returned 10.49% as of today's recent price of $91.59.
Look for Shares of Laboratory Corp of America Holdings to Potentially Pullback after Yesterday's 2.47% Rise
Comtex SmarTrend(R) - Mon Feb 10, 5:14PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $90.08 to a high of $91.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $91.39 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Laboratory Corp of America Holdings After 2.47% Gain
Comtex SmarTrend(R) - Mon Feb 10, 5:13PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $90.08 to a high of $91.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $91.39 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for Laboratory Corp of America Holdings (LH)
Comtex SmarTrend(R) - Mon Feb 10, 7:01AM CST
Laboratory Corp of America Holdings (NYSE:LH) was upgraded from Hold to Buy at Deutsche Bank today. The stock closed yesterday at $89.15 on volume of 2.3 million shares, above average daily volume of 967,000. Laboratory Corp of America Holdings share prices have moved between a 52-week high of $108.00 and a 52-week low of $87.01 and closed yesterday at 2% above that low price at $89.15 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 1.7%.
LabCorp Lags on Earnings & Revs, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 8:57AM CST
LabCorp reported fourth-quarter 2013 adjusted EPS of $1.61.
Barbarian At The Gate: Laboratory Corporation Of America Holdings (LH)
at The Street - Fri Feb 07, 8:54AM CST
Trade-Ideas LLC identified Laboratory Corporation of America Holdings (LH) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Laboratory Corporation of America(R) Holdings Announces 2013 Fourth Quarter and Full Year Results and Provides 2014 Guidance
Business Wire - Fri Feb 07, 6:10AM CST
--Non-GAAP Adjusted EPS Excluding Amortization of $1.61 and $6.95 for the Quarter and the Year, respectively (negative impact from weather was $0.03 and $0.07, respectively)
13.7% Return Seen to Date on SmarTrend Laboratory Corp of America Holdings Call (LH)
Comtex SmarTrend(R) - Wed Feb 05, 9:25AM CST
SmarTrend identified a Downtrend for Laboratory Corp of America Holdings (NYSE:LH) on November 29th, 2013 at $102.32. In approximately 2 months, Laboratory Corp of America Holdings has returned 13.73% as of today's recent price of $88.27.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
Myriad Genetics Down on Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 2:30PM CDT
Shares of Myriad Genetics slashed 8.34% at yesterday's close, soon after an unfavorable court bid.
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
Business Wire - Tue Mar 11, 4:05PM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that for the period of March 12, 2014 to September 11, 2014, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2014, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.56 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 27, 2014. The payment of contingent cash interest is expected to be made on September 11, 2014.
Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ
ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
LabCorp is Scheduled to Present at the Barclays Capital 2014 Global Healthcare Conference
Business Wire - Tue Mar 04, 4:05PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2014 Global Healthcare Conference in Miami Beach, FL. LabCorp's presentation is planned for Tuesday, March 11, 2014 at 10:45 AM (Eastern Time).
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
Must-See Charts: 5 Big Charts to Trade for Gains
at The Street - Thu Feb 27, 10:44AM CST
Here's a look at how to trade some of the biggest names on Wall Street.
Global Endocrine Testing Market to 2019: E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests
M2 - Wed Feb 26, 9:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/bk2st3/endocrine_testing) has announced the addition of the "Global Endocrine Testing Market to 2019: E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests" report to their offering. Endocrinology, a branch of medicine deals with the study of structural and functional elements of the endocrine system. This system comprises endocrine glands (thyroid, adrenal, pituitary and others) and secretory organs (pancreas, hypothalamus) that release hormones directly into the blood stream and regulate the body functioning. Endocrine testing market is studied by three major segments namely, by test, by diagnostic technologies and by end users. The test segment is further classified into 11 major hormone tests that includes estradiol (E2), Follicle Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), Luteinizing hormone (LH), Dehydroepiandrosterone sulfate (DHEAS), progesterone, testosterone, Thyroid Stimulating Hormone (TSH), prolactin, cortisol and insulin tests. The market accounts for a wide range of conventional as well as rapid diagnostic kits used for detecting deficiency (hyposecretion) or excess (hypersecretion) secretions of these hormones. The diagnostic technologies segment further describes the technological platforms used in the analysis of the specimen test sample (blood, urine, etc) and is further categorized into five major technologies, tandem mass spectrometry, immunoassay, monoclonal and polyclonal antibody, sensor and clinical chemistry technologies. The end user segment elucidates the endocrine testing market by various end users that includes hospitals, commercial laboratories, ambulatory health care centers, home based tests and physician's offices. The global endocrine testing market is segmented into the following categories: Tests - Estradiol (E2) Test - Follicle Stimulating Hormone (FSH) Test - Human Chorionic Gonadotropin (hCG) Test - Luteinizing Hormone (LH) Test - Dehydroepiandrosterone sulfate (DHEAS) Test - Progesterone Test - Testosterone Test - Thyroid Stimulating Hormone (TSH) Test - Prolactin Test - Cortisol Test - Insulin Test - Others (Gastrin, Thymosin, Secretin, etc.) Diagnostic Technologies - Tandem Mass spectrometry - Immunoassay (Enzyme immunoassays, Radioimmunoassays (RIA)) Technologies - Monoclonal and Polyclonal Antibody Technologies - Sensor (Electrochemical, Biosensors, etc.) Technologies - Clinical Chemistry Technologies - Others (Liquid Chromatography Mass Spectrometry (LC-MS), High performance Liquid Chromatography (HPLC), etc.) Location - Hospitals - Commercial Laboratories - Ambulatory Care Centers - Home Based Tests - Physician Offices Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Endocrine Testing Market, by Test Chapter 5 Endocrine Testing Market, by Diagnostic Technologies Chapter 6 Endocrine Testing Market, by End Users Chapter 7 Endocrine Testing Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned - Abbott Laboratories - AB SCIEX LLC - Agilent Technologies - Biomedical Diagnostics - bioMerieux - Bio-Rad Laboratories, Inc. - DiaSorin S.p.A - F. Hoffmann-La Roche Ltd. - Laboratory Corporation of America Holdings (LabCorp) - Ortho Clinical Diagnostics - Quest Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/bk...ne_testing
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
LabCorp Announces the Availability of Thermo Scientific ImmunoCAP(TM) Allergy Testing Products
Business Wire - Mon Feb 24, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the availability of Thermo Scientific ImmunoCAP(TM) allergy testing products from Thermo Fisher Scientific, Inc. (NYSE: TMO).
Illumina Expands in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 2:20PM CST
Recently, a HiSeq X Ten sequencing system of Illumina was acquired by a Chinese genomics service provider, Novogene.
Laboratory Corp of America Holdings Has Returned 10.5% Since SmarTrend Recommendation (LH)
Comtex SmarTrend(R) - Wed Feb 12, 11:22AM CST
SmarTrend identified a Downtrend for Laboratory Corp of America Holdings (NYSE:LH) on November 29th, 2013 at $102.32. In approximately 3 months, Laboratory Corp of America Holdings has returned 10.49% as of today's recent price of $91.59.
Look for Shares of Laboratory Corp of America Holdings to Potentially Pullback after Yesterday's 2.47% Rise
Comtex SmarTrend(R) - Mon Feb 10, 5:14PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $90.08 to a high of $91.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $91.39 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Laboratory Corp of America Holdings After 2.47% Gain
Comtex SmarTrend(R) - Mon Feb 10, 5:13PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $90.08 to a high of $91.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $91.39 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for Laboratory Corp of America Holdings (LH)
Comtex SmarTrend(R) - Mon Feb 10, 7:01AM CST
Laboratory Corp of America Holdings (NYSE:LH) was upgraded from Hold to Buy at Deutsche Bank today. The stock closed yesterday at $89.15 on volume of 2.3 million shares, above average daily volume of 967,000. Laboratory Corp of America Holdings share prices have moved between a 52-week high of $108.00 and a 52-week low of $87.01 and closed yesterday at 2% above that low price at $89.15 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 1.7%.
LabCorp Lags on Earnings & Revs, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 8:57AM CST
LabCorp reported fourth-quarter 2013 adjusted EPS of $1.61.
Barbarian At The Gate: Laboratory Corporation Of America Holdings (LH)
at The Street - Fri Feb 07, 8:54AM CST
Trade-Ideas LLC identified Laboratory Corporation of America Holdings (LH) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Laboratory Corporation of America(R) Holdings Announces 2013 Fourth Quarter and Full Year Results and Provides 2014 Guidance
Business Wire - Fri Feb 07, 6:10AM CST
--Non-GAAP Adjusted EPS Excluding Amortization of $1.61 and $6.95 for the Quarter and the Year, respectively (negative impact from weather was $0.03 and $0.07, respectively)
13.7% Return Seen to Date on SmarTrend Laboratory Corp of America Holdings Call (LH)
Comtex SmarTrend(R) - Wed Feb 05, 9:25AM CST
SmarTrend identified a Downtrend for Laboratory Corp of America Holdings (NYSE:LH) on November 29th, 2013 at $102.32. In approximately 2 months, Laboratory Corp of America Holdings has returned 13.73% as of today's recent price of $88.27.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
